107 related articles for article (PubMed ID: 14741157)
1. Incorporation of CpG oligodeoxynucleotide fails to enhance the protective efficacy of a subunit vaccine against Mycobacterium tuberculosis.
Hsieh MJ; Junqueira-Kipnis AP; Hoeffer A; Turner OC; Orme IM
Vaccine; 2004 Jan; 22(5-6):655-9. PubMed ID: 14741157
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis.
Freidag BL; Melton GB; Collins F; Klinman DM; Cheever A; Stobie L; Suen W; Seder RA
Infect Immun; 2000 May; 68(5):2948-53. PubMed ID: 10768993
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone.
Wedlock DN; Denis M; Skinner MA; Koach J; de Lisle GW; Vordermeier HM; Hewinson RG; van Drunen Littel-van den Hurk S; Babiuk LA; Hecker R; Buddle BM
Infect Immun; 2005 Jun; 73(6):3540-6. PubMed ID: 15908383
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and CpG oligodeoxynucleotides induces protection against bovine tuberculosis.
Wedlock DN; Skinner MA; de Lisle GW; Vordermeier HM; Hewinson RG; Hecker R; van Drunen Littel-van den Hurk S; Babiuk LA; Buddle BM
Vet Immunol Immunopathol; 2005 Jun; 106(1-2):53-63. PubMed ID: 15910992
[TBL] [Abstract][Full Text] [Related]
5. Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion.
da Fonseca DM; Silva CL; Wowk PF; Paula MO; Ramos SG; Horn C; Marchal G; Bonato VL
Infect Immun; 2009 Dec; 77(12):5311-21. PubMed ID: 19752029
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.
Fonseca DM; Silva CL; Paula MO; Soares EG; Marchal G; Horn C; Bonato VL
Immunology; 2007 Aug; 121(4):508-17. PubMed ID: 17433075
[TBL] [Abstract][Full Text] [Related]
7. Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.
Todoroff J; Lemaire MM; Fillee C; Jurion F; Renauld JC; Huygen K; Vanbever R
PLoS One; 2013; 8(5):e63344. PubMed ID: 23675482
[TBL] [Abstract][Full Text] [Related]
8. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
[TBL] [Abstract][Full Text] [Related]
9. CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection.
Hu S; Chen H; Ma J; Chen Q; Deng H; Gong F; Huang H; Shi C
J Appl Microbiol; 2013 Nov; 115(5):1203-11. PubMed ID: 23902541
[TBL] [Abstract][Full Text] [Related]
10. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice.
Wu J; Ma H; Qu Q; Zhou WJ; Luo YP; Thangaraj H; Lowrie DB; Fan XY
Vaccine; 2011 Oct; 29(44):7624-30. PubMed ID: 21856352
[TBL] [Abstract][Full Text] [Related]
12. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection.
Trentini MM; de Oliveira FM; Gaeti MP; Batista AC; Lima EM; Kipnis A; Junqueira-Kipnis AP
Vaccine; 2014 Jul; 32(34):4324-32. PubMed ID: 24951861
[TBL] [Abstract][Full Text] [Related]
13. MPT-51/CpG DNA vaccine protects mice against Mycobacterium tuberculosis.
Silva BD; da Silva EB; do Nascimento IP; Dos Reis MC; Kipnis A; Junqueira-Kipnis AP
Vaccine; 2009 Jul; 27(33):4402-7. PubMed ID: 19500525
[TBL] [Abstract][Full Text] [Related]
14. Protective Vaccine Efficacy of the Complete Form of PPE39 Protein from Mycobacterium tuberculosis Beijing/K Strain in Mice.
Kim A; Hur YG; Gu S; Cho SN
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877927
[TBL] [Abstract][Full Text] [Related]
15. A Promising Listeria-Vectored Vaccine Induces Th1-Type Immune Responses and Confers Protection Against Tuberculosis.
Yin Y; Lian K; Zhao D; Tao C; Chen X; Tan W; Wang X; Xu Z; Hu M; Rao Y; Zhou X; Pan Z; Zhang X; Jiao X
Front Cell Infect Microbiol; 2017; 7():407. PubMed ID: 29034213
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis.
Ballester M; Nembrini C; Dhar N; de Titta A; de Piano C; Pasquier M; Simeoni E; van der Vlies AJ; McKinney JD; Hubbell JA; Swartz MA
Vaccine; 2011 Sep; 29(40):6959-66. PubMed ID: 21787826
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and protective efficacy of a DNA vaccine encoding the fusion protein of mycobacterium heat shock protein 65 (Hsp65) with human interleukin-2 against Mycobacterium tuberculosis in BALB/c mice.
Wang LM; Bai YL; Shi CH; Gao H; Xue Y; Jiang H; Xu ZK
APMIS; 2008 Dec; 116(12):1071-81. PubMed ID: 19133010
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
[TBL] [Abstract][Full Text] [Related]
20. Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.
Triccas JA; Shklovskaya E; Spratt J; Ryan AA; Palendira U; Fazekas de St Groth B; Britton WJ
Infect Immun; 2007 Nov; 75(11):5368-75. PubMed ID: 17724075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
